Overview

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Helsinn Therapeutics (U.S.), Inc